Immunotherapy for Alzheimer's disease: Hoops and hurdles

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Lemere, Cynthia A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Amyloid ; BACE 1; Immunotherapy; Pyroglutamate A ; Tau; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; CANCER VACCINE; CRENEZUMAB; GANTENERUMAB; IMMUNOGLOBULIN G; MER 5101; SOLANEZUMAB; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DEMENTIA; HUMAN; IMMUNOTHERAPY; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION;

ANIMALIA;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; ANIMALS; HUMANS; IMMUNOTHERAPY;

EID: 84886937126     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-36     Document Type: Article

References (38)

1. Alzheimer's disease facts and figures. Alzheimer's Association, Alzheimers Dement 2013 9 2 1 71 23305821
2. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Perrin RJ, Fagan AM, Holtzman DM, Nature 2009 461 916 922 10.1038/nature08538 19829371
3. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
4. Can Alzheimer's disease be prevented by amyloid β immunotherapy? Lemere CA, Masliah E, Nat Rev Neurol 2010 6 108 119 10.1038/nrneurol.2009.219 20140000
5. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Solomon B, Koppel R, Hanan E, Katzav T, Proc Natl Acad Sci U S A 1996 93 452 455 10.1073/pnas.93.1.452 8552659 (Pubitemid 26038175)
6. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Solomon B, Koppel R, Frenkel D, Hanan-Aharon E, Proc Natl Acad Sci USA 1997 94 4109 4112 10.1073/pnas.94.8.4109 9108113 (Pubitemid 27180507)
7. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P, Nature 1999 400 173 177 10.1038/22124 10408445 (Pubitemid 29327547)
8. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo J-M, Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
9. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR, Lancet 2008 372 216 223 10.1016/S0140-6736(08)61075-2 18640458 (Pubitemid 351978111)
10. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease. Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JAR, Acta Neuropathol 2010 120 13 20 10.1007/s00401-010-0705-y 20532897
11. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. Ryan JM, Grundman M, J Alzheimer Dis 2009 17 243
12. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennw K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A, Lancet Neurol 2012 11 597 604 10.1016/S1474-4422(12)70140-0 22677258
13. Development of Affitope vaccines for Alzheimer's disease (AD)-from concept to clinical testing. Schneeberger A, Mandler M, Otava O, Zauner W, Mattner F, Schmidt W, J Nutr Health Aging 2009 13 264 267 10.1007/s12603-009- 0070-5 19262965
14. Liposomal vaccines with conformation-specific amyloid antigens define immune response and efficacy in APP transgenic mice. Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens N, Meerschman C, van der Auwera I, Van Leuven F, Sugawara M, Weingertner M-C, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C, Proc Natl Acad Sci USA 2007 104 9810 9815 10.1073/pnas.0703137104 17517595 (Pubitemid 47175348)
15. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T, Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
16. §ssup§11§esup§C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello KA, Rodriguez Martinez de Llano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
17. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M, Science 2002 298 1379 10.1126/science.1078259 12434053 (Pubitemid 35346131)
18. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D, J Neuroinflammation 2004 1 24 10.1186/1742-2094-1-24 15588287 (Pubitemid 40617823)
19. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB, J Neurosci 2005 25 629 636 10.1523/JNEUROSCI.4337-04.2005 15659599
20. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Grundman M, Lancet Neurol 2012 11 241 249 10.1016/S1474-4422(12)70015-7 22305802
21. Peripheral anti-a beta antibody alters CNS and plasma a beta clearance and decreases brain a beta burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM, Proc Natl Acad Sci U S A 2001 98 8850 8855 10.1073/pnas.151261398 11438712 (Pubitemid 32678116)
22. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Dodart J-C, Bales K, Gannon K, Greene S, DeMattos R, Mathis C, DeLong C, Wu S, Wu X, Holtzman D, Paul S, Nature Neurosci 2002 5 452 457 11941374 (Pubitemid 34454251)
23. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Farlow M, Arnold SE, Van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER, Alzheimers Dement 2012 8 261 271 10.1016/j.jalz.2011.09.224 22672770
24. Lilly Press Release, 2012 https://investor.lilly.com/releasedetail.cfm? releaseid=711933
25. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango-L JC, Anthony DC, Koo E, Goate A, Selkoe DJ, Arango-V JC, Nat Med 1996 2 1146 1150 10.1038/nm1096-1146 8837617 (Pubitemid 26338637)
26. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapie L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS, JAMA 1997 277 793 799 10.1001/jama.1997.03540340027028 9052708 (Pubitemid 27111314)
27. An effector-reduced anti-Aβ-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ, J Neurosci 2012 32 9677 9689 10.1523/JNEUROSCI.4742-11.2012 22787053
28. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H, J Alzheimers Dis 2012 28 49 69 21955818
29. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S, Neuron 1995 14 457 466 10.1016/0896-6273(95) 90301-1 7857653
30. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU, Biochemistry 2006 45 12393 12399 10.1021/bi0612667 17029395 (Pubitemid 44583682)
31. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer's-like transgenic mice: a pilot study. Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth H-U, Lemere CA, Neurodegenerative Dis 2012 10 265 270 10.1159/000335913
32. Identification of low molecular weight pyroglutamate Aβ oligomers in Alzheimer disease. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawar S, Kuma S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA, J Biol Chem 2010 285 41517 41724 10.1074/jbc.M110.178707 20971852
33. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML, Neuron 2012 76 908 920 10.1016/j.neuron.2012.10.029 23217740
34. Intraveneous immunoglobulin and Alzheimer's disease: what now? Loeffler DA, J Neuroinflammation 2013 10 70 doi:10.1186/1742-2094-10-70 10.1186/1742-2094-10-70 23735288
35. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F, Lancet Neurol 2013 12 233 243 10.1016/S1474-4422(13)70014-0 23375965
36. Alzforum News, GammagardTM misses endpoints in phase 3 trial http://www.alzforum.org/new/detail.asp?id=3485
37. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Rosemann H, Curr Alzheimer Res 2013 10 217 228 10.2174/ 1567205011310030001 23534533
38. MER5101, a Novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1dE9 transgenic mice. Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA, J Neurosci 2013 33 7027 7037 10.1523/JNEUROSCI.5924- 12.2013 23595760